Search Results for: clinicaltrials.gov

Review of Docere Clinics run by Harry Adelson including total-body injections

Amy Killen, Docere Clinic

In today’s post, I reviewed a stem cell clinic firm called Docere Clinics. In my opinion, there are some concerning issues here and reasons for caution. One type of procedure at Docere is particularly surprising and raises risks in my view. What is Docere Clinics? | What kind of stem cells does Docere use? | What they […]

Review of Docere Clinics run by Harry Adelson including total-body injections Read More »

3 cell therapy companies doing well: Vertex, Vericel, & Regeneron

Vericel, Cell Therapy Companies

Cell therapy companies face many hurdles. I wrote recently about four cell therapy biotechs that have been really struggling. Blogging here at The Niche for more than a dozen years, I’ve seen many companies even go under. That’s bad news for the field, for patients, and for investors. Today I wanted to highlight some cell therapy

3 cell therapy companies doing well: Vertex, Vericel, & Regeneron Read More »

Weekly reads: stem cells for epilepsy from Neurona Therapeutics, diabetes, contagious cancer

Neurona Therapeutics, stem cells for epilepsy

People often ask me what are the most promising stem cell therapies in development and new data suggest we should add stem cells for epilepsy to the list based on work by Neurona Therapeutics. I’ll start off the weekly recommended reads with this new mouse paper on cell therapy for epilepsy. Neurona Therapeutics: stem cells

Weekly reads: stem cells for epilepsy from Neurona Therapeutics, diabetes, contagious cancer Read More »

Weekly reads: CRISPR sickle cell, Parkinson’s, pig-human chimera concerns

CRISPR gene editing

CRISPR gene editing has made rapid progress heading from bench to bedside. Perhaps the fastest has been its progress toward clinical use to combat sickle cell disease. We’ll start with a new paper on one major effort here. CRISPR gene editing. This process often involves cutting DNA, which then can be used as an opening to

Weekly reads: CRISPR sickle cell, Parkinson’s, pig-human chimera concerns Read More »

Weekly reads: BioCardia, HeLa suit, illegal bio lab in CA

mesenchymal cells

A days ago the news came about Mesoblast not getting FDA approval for its MSC product for GvHD. The MSC area has had a rough few years with various clinical trials including for COVID. The “stem cells for heart disease” arena has also had a tough time. Here’s more news along these lines: BioCardia pauses enrollment in PhIII trial

Weekly reads: BioCardia, HeLa suit, illegal bio lab in CA Read More »

Update on stem cells & cell therapy for COVID trials

cell therapy for COVID

From the beginning of the pandemic, I have been mostly skeptical about the idea of cell therapy for COVID including stem cell therapies. However, at the same time, I’ve closely followed the data, especially up until 2022. Now having just had a nasty bout with COVID myself for the first time this summer, I recently

Update on stem cells & cell therapy for COVID trials Read More »

Long telomeres link to disease suggests caution on anti-aging push

long telomeres

Are long telomeres better than short ones? What about older folks lengthening their telomeres somewhat or stabilizing the length? Could this counter aging? As with many things, the story is far more complicated than we might hope. For background, telomeres are special structures protecting the ends of chromosomes. I remember as a young student that

Long telomeres link to disease suggests caution on anti-aging push Read More »

Review of where Kimera Labs fits into sphere of exosome companies

Kimera labs exosome

Today’s post takes a close look at the exosome manufacturer Kimera Labs in the context of the main exosome companies. What are exosomes? Exosomes are microscopic bubbles or vesicles produced by cells. Exosomes contain many cellular substances that are biologically active. Some of these materials may be helpful clinically, while others could pose risks. Clinical outcomes

Review of where Kimera Labs fits into sphere of exosome companies Read More »